News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,105 Results
Type
Article (8021)
Company Profile (140)
Press Release (475847)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166764)
Career Advice (305)
Deals (25742)
Drug Delivery (7)
Drug Development (52885)
Employer Resources (14)
FDA (9761)
Job Trends (8577)
News (238251)
Policy (17922)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (23)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33161)
ALS (103)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (261)
Approvals (10362)
Artificial intelligence (317)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6965)
BIO (36)
BIOSECURE Act (1)
Biosimilars (107)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (504)
Cancer (3614)
Cardiovascular disease (216)
Career advice (246)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (473)
Cervical cancer (34)
Clinical research (47818)
Collaboration (1227)
Commercialization (2)
Compensation (1427)
Complete response letters (34)
COVID-19 (759)
CRISPR (63)
C-suite (728)
Cystic fibrosis (84)
Data (5579)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (339)
Diagnostics (4173)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73451)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87572)
Executive appointments (696)
FDA (12349)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (900)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (949)
Grass and pollen (2)
Guidances (280)
Healthcare (9324)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (947)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (249)
Interviews (42)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (5)
Liver cancer (44)
Longevity (15)
Lung cancer (501)
Lymphoma (248)
Machine learning (27)
Management (3)
Manufacturing (523)
Marketing (7)
MASH (117)
Medical device (8649)
Medtech (8786)
Mergers & acquisitions (14374)
Metabolic disorders (699)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (38)
Neuroscience (1811)
NextGen: Class of 2026 (3155)
Non-profit (846)
Obesity (221)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (193)
Parkinson's disease (200)
Partnered (11)
Patents (464)
Patient recruitment (496)
Peanut (31)
People (41200)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15455)
Phase 2 (21356)
Phase 3 (14384)
Pipeline (6994)
Policy (18)
Postmarket research (1572)
Preclinical (6532)
Press Release (34)
Prostate cancer (188)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (567)
Real estate (3021)
Recruiting (6)
Regulatory (14775)
Reports (17)
Research institute (580)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (151)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (77)
Date
Today (16)
Last 7 days (521)
Last 30 days (1416)
Last 365 days (19042)
2026 (11635)
2025 (19252)
2024 (22986)
2023 (26541)
2022 (34588)
2021 (37181)
2020 (33482)
2019 (23257)
2018 (17493)
2017 (18766)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (227)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17870)
Australia (2095)
California (11765)
Canada (3093)
China (510)
Colorado (475)
Connecticut (400)
Delaware (205)
Europe (24599)
Florida (1755)
Georgia (372)
Hawaii (3)
Idaho (46)
Illinois (691)
India (45)
Indiana (314)
Iowa (14)
Japan (395)
Kansas (99)
Kentucky (30)
Louisiana (26)
Maine (25)
Maryland (1180)
Massachusetts (7759)
Michigan (304)
Minnesota (555)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2586)
New Mexico (12)
New York (2785)
North Carolina (1255)
North Dakota (4)
Northern California (5875)
Ohio (273)
Oklahoma (14)
Oregon (16)
Pennsylvania (2231)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4887)
Tennessee (116)
Texas (1899)
United States (38283)
Utah (356)
Vermont (1)
Virginia (151)
Washington D.C. (38)
Washington State (910)
West Virginia (1)
Wisconsin (73)
484,105 Results for "apollomics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
July 13, 2026
·
3 min read
Press Releases
Apollomics Inc. Announces $2.0 Million Bridge Financing
April 1, 2026
·
4 min read
Press Releases
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
June 24, 2026
·
5 min read
Press Releases
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
April 27, 2026
·
10 min read
Press Releases
Apollomics, Inc. Company Operational Continuity Update
October 14, 2025
·
6 min read
Press Releases
Apollomics Reports First Half 2025 Financial Results
December 23, 2025
·
5 min read
Press Releases
Apollomics Announces Changes to its Board of Directors and Composition of Committees
November 18, 2025
·
4 min read
Biotech Bay
Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Inc. announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
May 29, 2024
·
1 min read
Business
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
March 4, 2024
·
5 min read
Press Releases
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
April 1, 2025
·
7 min read
1 of 48,411
Next
